The regulation of human blood glucose concentration is mainly achieved by the mutual restriction of insulin and glucagon at multiple levels. Among them, insulin produced by islet β cells is responsible for promoting blood glucose absorption and lowering blood glucose concentration. Islet beta cell destruction or dysfunction can lead… Continue Reading Nature’s paper: Treating diabetes with cell therapy is worth looking forward to
On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor, Forxiga (Dalagide) as adjunctive therapy for insulin, for optimal use of optimal doses of insulin to control poor blood sugar. Type 1 diabetes patients (BMI ≥ 27). This is the first time that… Continue Reading SGLT-2 inhibitors first approved for the treatment of type 1 diabetes
Gump’s troubles In 2013, Gump’s actor, the second American movie star Tom Hanks, who won the Oscar for Best Actor Award for two consecutive years, frankly told the hosts and viewers on a nighttime talk show: “When I went to see a doctor, he said to me, ‘Do you… Continue Reading From lizard venom to a new drug for type 2 diabetes – Lyxumia
Alzheimer’s disease may have originated from some unknown type of diabetes! This rather shocking hypothesis is expected to open up new avenues for the treatment of Alzheimer’s disease and even to find preventive measures. “Alzheimer’s disease is diabetes in the brain.” This remark first aroused great repercussions in the field… Continue Reading Is Alzheimer’s disease called “Type III” diabetes?
In a large LEADER study involving 9340 patients with type 2 diabetes with higher cardiovascular risk, liraglutide reduced the risk of cardiovascular death, non-fatal MI, and non-fatal stroke by 13%. The risk of death was reduced by 15% and the risk of cardiovascular death was reduced by 22%. At the… Continue Reading Liraglutide: Got natural hypoglycemic, part-time weight loss, but dislike for no effect on heart failure?
According to the forecast of Datamonitor Healthcare, the weight loss market in the United States will grow from the current 5.3 billion US dollars to 1.2 billion US dollars over the next decade. However, if a more effective treatment plan emerges, the market may experience dramatic growth. It is understood… Continue Reading The next decade of the diet pill market
Improper use of drugs not only compromises curative effect, but also causes drug intolerance or adverse reactions. Therefore, when using metformin in patients with diabetes, the doctor needs to formulate the dose and usage of the drug according to the actual situation of the patient to accurately grasp the efficacy… Continue Reading Three drug details of metformin